George Simeon

Role: CEO at Curevo Vaccine
Location: Seattle, WA, US
LinkedIn followers: 500 followers

General Business & ManagementView LinkedIn profile

About George Simeon

Strategic Alliances, Global Commercialisation, M&A, Joint-Ventures, Organization…

Experience

CEO
Curevo Vaccine
Feb 2019 — Present
Vaccine Development, specializing in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development.

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@curevovaccine.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Curevo Vaccine

Biotechnology Research · 44 employees · Founded 2017 · Bothell, Washington, United States

Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.

curevovaccine.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About George Simeon

Experience

CEO

Find verified contacts for anyone on LinkedIn